| This week's sponsor is Premier Research. | | | Rare Cancer Drug Research: What to Know Going In
Rare cancer drug research requires oncology and rare disease expertise and careful attention to trial design and regulatory demands. Get started with our white paper. Premier Research. It's what we do. Best. |
Today's Rundown | Publisher’s Note: In preparation for the new GDPR taking effect this month, we would like to reconfirm your subscription to our newsletter(s). Please click this link to reconfirm your subscription. For more information about GDPR, please visit this page. | |
|
AstraZeneca drops Amgen-partnered solid tumor drug Janssen drops the BACE as Alzheimer’s candidate joins fail list Takeda to cut 'moderately innovative' R&D after $62B Shire buy: Reuters [Sponsored] Accelerating Timelines for Rare Disease Drug Development Seattle Genetics names former Keytruda developer as CMO Accent Therapeutics reels in $40M to target RNA-modifying proteins in cancer BMS in vivo study director joins Apexigen to lead antibody discovery Amgen's Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price? EuroBiotech Report—Bluebird-Medigene, Novo, MeiraGTx IPO, U.K. biotech and Faron FiercePharmaAsia—WuXi’s and Sinobioway’s new sites, Takeda’s financials and R&D plan Chutes and Ladders—Seattle Genetics names former Keytruda developer as CMO Featured Story | | | Friday, May 18, 2018 AstraZeneca has dropped Amgen-partnered bispecific T-cell engager MEDI-565 from its clinical-phase pipeline. The CEA-CD3 candidate was pitched as a treatment for colorectal cancer but looks to have come unstuck in early-phase trials. |
|
|
Top Stories Friday, May 18, 2018 Johnson & Johnson’s Janssen unit has joined the far-from-exclusive Alzheimer's disease failure club after deciding to terminate trials of its BACE inhibitor atabacestat. Thursday, May 17, 2018 CEO Christophe Weber's plan involves signing on one or more large, long-term investors, as well as keeping its R&D pipeline alive by discarding programs that don't deliver. Monday, May 14, 2018 For children diagnosed with rare diseases, traditional drug development timelines are not good enough. Collaborative partnerships are imperative to accelerate those timelines and expedite time to market for rare disease therapies. Thursday, May 17, 2018 Seattle Genetics appointed Roger Dansey as its chief medical officer. He previously helped lead Merck’s late-stage oncology work, including research on Keytruda in multiple tumor types. Friday, May 18, 2018 Accent is working to understand which RNA-modifying proteins are involved in which cancer indications, and to develop drugs to target them. Friday, May 18, 2018 Frances Rena Bahjat, Bristol-Myers Squibb’s former senior director of in vivo studies, has joined Apexigen in the newly created role of vice president for discovery research. Thursday, May 17, 2018 Amgen and Novartis inaugurated a much-anticipated new class of migraine drugs Wednesday with FDA approval for Aimovig, an injectable medication laden with blockbuster hopes. But Aimovig has several more hurdles to clear before it can reach those lofty goals—including persuading payers it's worth the cost of $6,900 per year. Thursday, May 17, 2018 In this week's EuroBiotech Report, Bluebird and Medigene expand their TCR pact; Novo pushes into stem cell therapies; MeiraGTx files for IPO and more. Friday, May 18, 2018 China's WuXi Biologics and Sinobioway are investing hundreds of millions of dollars on biologics facilities; Takeda sees 40% drop in Velcade sales for 2018 and is looking to offload "moderately innovative" assets in its pipeline to cut costs; and more. Friday, May 18, 2018 Seattle Genetics names former Keytruda developer as CMO; ex-Pfizer executives join Roivant’s C-suite; Aravive CEO Stephen Eck leaves to join Immatics; plus more hirings, firings and retirings throughout the industry. | This week's sponsor is Eurofins Advinus. | | | |
Resources Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: USDM Life Sciences What are the biggest trends in life sciences this year? Presented by: Patheon There are many parenteral dosage forms from which the pharmaceutical scientist can choose to develop their drug product. In this article, the author discusses the choices available and strategies which can be employed at the different stages of development. Sponsored by: Veeva Systems Explore a new model for events management, and learn how to deliver more value. Sponsored by: Veeva Systems To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights. Sponsored by: Veeva Systems Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams. Sponsored by: Veeva Systems Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems. Sponsored by: Veeva Systems UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off. Sponsored by: Veeva Systems Find out how to eliminate regulatory’s tracking spreadsheets for good. Sponsored by: Veeva Systems Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Building your Program for Immunomodulating Therapeutics Wednesday, 6 June, 2018 | Paris, France BIO International Convention June 4-7, 2018 | Boston, MA
FierceBiotech Executive Breakfast at BIO 2018 – CAR-T 2.0: Innovation Never Stands Still June 6, 2018 | Boston, MA BioBasics: Biotech for the Non-Scientist June 13-14, 2018 | Toronto, Canada Sensors Expo & Conference Conference & Expo: June 26-28, 2018 | Pre-Conference Symposia: June 25, 2018 | San Jose, CA FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 